Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,322 across all filing types
Latest filing 2024-10-21 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2024-10-21 English
Loss of Share Certificate(s)
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about the loss of share certificates by shareholders, referencing SEBI regulations. It lists specific shareholders, folio numbers, certificate numbers, and distinctive share numbers. This is a regulatory disclosure related to share certificates but does not involve financial results, management changes, or capital structure changes. It is not a report, announcement of voting results, or a share issue. The content fits best under Regulatory Filings (RNS) as it is a compliance disclosure that does not fit other specific categories.
2024-10-18 English
FORM 6-K
Regulatory Filings
2024-10-15 English
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Legal Proceedings Report Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically covers material events or information that a listed company must disclose to stock exchanges. The content describes ongoing legal proceedings involving the company and its subsidiaries, including details about lawsuits and court orders. It is an update on legal matters rather than a full legal proceedings report or a financial report. The document is relatively short (2858 characters) and serves as a regulatory announcement to stock exchanges about litigation developments. Therefore, it fits best under the category of Legal Proceedings Report (LTR).
2024-10-14 English
Issue of Letter of confirmation in lieu of share certificate(s) reported lost/ misplaced
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the issuance of Letters of Confirmation or credit of shares in lieu of share certificates reported lost or misplaced by shareholders. It references SEBI regulations related to share certificate replacement. The content is an official notification about share certificate replacement and does not contain financial statements, earnings data, management discussion, or any report publication. It is not an annual report, earnings release, or any financial report. It is also not a voting result, board change, or capital change announcement. The document is a regulatory compliance communication informing the stock exchanges about share certificate replacements. Given the nature and length (2131 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-11 English
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the voluntary liquidation of a wholly owned subsidiary of the company. It references prior disclosures and approvals by the Board of Directors and shareholders. The content is an update on a corporate action (liquidation of a subsidiary) and includes details required under SEBI regulations. The document is relatively short (3630 characters) and serves as a regulatory disclosure rather than a full financial report or detailed analysis. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of voting results, nor a proxy solicitation, nor a remuneration report. The document fits best as a Regulatory Filing (RNS) because it is a compliance disclosure under SEBI regulations about a corporate event, without being a full report or announcement of a report publication.
2024-10-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.